Paul Hastings LLP’s full-service patent litigation practice is reputed for its technical expertise and success in representing notable clients in the life sciences and technology sectors, including Meta, Google, Samsung and BioNTech. The team often works on precedent-setting matters, such as their recent victory for Allergan which will transform Obviousness-type Double Patenting (ODP) in the pharmaceutical industry. The practice also showcases expertise in high-value trade secret matters. Chairing the practice are three IP specialists: Naveen Modi, located in Washington DC, is an expert in post-grant patent and appellate proceedings, particularly before the USPTO and Court of Appeals; New York’s Bruce Wexler, who focuses on life sciences patent litigation and represents large and start-up biotech companies; and Eric Dittmann, who is also based in New York and is seasoned in trying business-critical patent cases, with a core focus on biotech and Hatch-Waxman cases. Another key contact in New York is Melanie Rupert whose experiences extend to the biotech, pharmaceutical and medical device industries. Lisa Nguyen, along with five fellow partners, joined the team in March 2024 from A&O Shearman.
Legal 500 Editorial commentary

Key clients

  • Meta Platforms
  • Google LLC

Work highlights

Triumphed on behalf of Allergan as the Federal Circuit fully revived claims of patents covering Allergan's bowel treatment drug Viberzi, effectively transforming the doctrine of Obviousness-type Double Patenting (“ODP”) in a closely watched decision impacting virtually every major pharmaceutical product in the market. The ODP issue will impact hundreds of billions (if not trillions) in pharmaceutical product sales.

Lawyers

Leading partners

The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.

Practice head

Naveen Modi; Bruce Wexler; Eric Dittmann

Other key lawyers

Melanie Rupert; Lisa Nguyen